登录

QIAGEN推出专为肿瘤学和遗传病生物信息学工作流量身定制的新二次分析解决方案

QIAGEN Launches New Secondary Analysis Solution Tailored for Oncology and Inherited Disease Bioinformatics Workflows

PHARMA FOCUS ASIA | 2024-05-03 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


QIAGEN has introduced QCI Secondary Analysis, a cloud-based software-as-a-service (SaaS) solution that facilitates high-throughput secondary analysis for clinical next-generation sequencing (NGS) data. This platform seamlessly integrates with QCI Interpret, QIAGEN's clinical variant interpretation and reporting software, and supports all QIAGEN QIAseq panels.Traditionally, sequencing data goes through three phases: primary analysis, secondary analysis, and tertiary analysis.

QIAGEN推出了QCI二次分析,这是一种基于云的软件即服务(SaaS)解决方案,可促进临床下一代测序(NGS)数据的高通量二次分析。该平台与QIAGEN的临床变异解释和报告软件QCI Interpret无缝集成,并支持所有QIAGEN QIAseq面板。传统上,测序数据经历三个阶段:初级分析,二级分析和三级分析。

QCI Secondary Analysis focuses on the secondary analysis stage, where DNA fragments are assembled and analyzed for variants in relation to a reference genome. This tool simplifies the bioinformatics pipeline, making NGS testing more accessible to labs of varying sizes and expertise levels.The platform is designed to streamline analysis from various assay types, minimizing resource investment while maximizing productivity.

QCI二级分析侧重于二级分析阶段,在该阶段组装DNA片段并分析与参考基因组相关的变体。该工具简化了生物信息学流程,使不同规模和专业水平的实验室更容易进行NGS测试。该平台旨在简化各种分析类型的分析,最大限度地减少资源投资,同时最大限度地提高生产力。

It is deployed on the secure QIAGEN Clinical Cloud, ensuring data protection and compliance with regulatory standards such as ISO 27001, GDPR, and HIPAA.QCI Secondary Analysis complements QIAGEN's Sample to Insight portfolio, providing validated support for QIAseq panels, integration with QCI Interpret, and compatibility with other QIAGEN software modules like LightSpeed Clinical.

它部署在安全的QIAGEN临床云上,确保数据保护和遵守ISO 27001、GDPR和HIPAA等监管标准。QCI二次分析补充了QIAGEN的Sample to Insight产品组合,为QIAseq面板提供了经过验证的支持,与QCI Interpret集成,并与其他QIAGEN软件模块(如LightSpeed Clinical)兼容。

QIAGEN Digital Insights solutions empower researchers and clinicians worldwide, facilitating data processing and interpretation for improved research outcomes.For labs interested in leveraging comprehensive genomic information, QCI Secondary Analysis offers a user-friendly, turnkey solution. With its ability to process more sequencing data efficiently, this platform represents a significant advancement in precision medicine accessibility. Source: qiagen.com.

QIAGEN Digital Insights解决方案为全球研究人员和临床医生提供了强大的支持,促进了数据处理和解释,从而改善了研究结果。对于有兴趣利用全面基因组信息的实验室,QCI二次分析提供了一个用户友好的交钥匙解决方案。凭借其高效处理更多测序数据的能力,该平台代表了精准医学可及性的重大进步。来源:qiagen.com。

推荐阅读

华大智造、Illumina、赛默飞等多家测序仪公司发布2024 Q1财报

测序中国 2024-05-16 17:15

QIAGEN的临床决策支持医疗设备软件QIAGEN Clinical Insight Interpret获得欧洲IVDR认证

BioSpace 2024-05-14 22:52

分子诊断产品研发商QIAGEN宣布QIAstat-Dx呼吸系统综合征检测组合获FDA认证

GlobeNewswire 2024-05-13 14:00

PHARMA FOCUS ASIA

130篇

最近内容 查看更多

Parallel Bio推出利用类器官加速药物发现的新型临床试验方法

10 小时前

生物仿制药生产销售商Glenmark酒石酸溴莫尼定和马来酸噻吗洛尔眼科溶液(0.2%|0.5%)获FDA批准

12 小时前

葛兰素史克疫苗Arexvy获得HSA批准,针对老年人的呼吸道合胞病毒

2 天前

相关公司查看更多

QIAGEN

分子检测解决方案技术提供商及分子诊断产品研发、生产商

立即沟通

产业链接查看更多

所属赛道

IVD
近30天,融资5起
分子诊断
近30天,融资2起
动脉橙产业智库梳理了:分子诊断相关公司以及投融资和并购事件800+;近10年体外诊断相关政策超过150条;产业图谱、资本风云、技术与产品等分析维度,并将持续更新。